ASCO Launches Groundbreaking Clinical Trial to Revolutionize Cancer Treatment

The American Society of Clinical Oncology (ASCO) has announced the launch of its first-ever clinical trial, the Targeted Agent and Profiling Utilization Registry (TAPUR) study, aimed at providing patients with advanced cancer access to molecularly-targeted cancer drugs and collecting "real-world" data on clinical outcomes. The trial will offer patients a broader range of treatment options and will be conducted in collaboration with major pharmaceutical companies, technology firms, and community-based research programs. The study's goal is to document the real-world experience of patients receiving commercially available targeted anti-cancer drugs and describe their effectiveness and side effects.

Key Takeaways:

• The TAPUR study will collect information on the anti-tumor activity and toxicity of commercially available, targeted cancer drugs in a range of cancer types, including advanced solid tumors, multiple myeloma, and non-Hodgkin lymphoma with a genomic variation known to be a drug target.
• The study will accept patients who have any advanced solid tumor, multiple myeloma, or B cell non-Hodgkin lymphoma and are no longer responding to standard anti-cancer treatment or for whom no acceptable treatment is available.
• Patients will be monitored for standard toxicity and efficacy outcomes, including tumor response, progression-free and overall survival, as well as duration of treatment.
• The study will provide patients with the anti-cancer drugs at no charge, with routine clinical care costs covered by the patient's insurance plan.
• At least 13 drugs that target more than 15 unique genomic variants will be provided by participating pharmaceutical companies, including AstraZeneca, Bristol-Myers Squibb, Eli Lilly and Company, Genentech, and Pfizer.
• The study will be conducted at clinical sites that comprise the Michigan Cancer Research Consortium, the Cancer Research Consortium of West Michigan, and the Carolinas Healthcare System.
• Patient advocates will play a central role throughout the study, providing guidance and oversight support, and will be recruited and trained by Jane Perlmutter, PhD, a cancer survivor and nationally recognized patient advocate.

Statistics:

• The TAPUR study will include patients with advanced cancer who are no longer responding to standard anti-cancer treatment or for whom no acceptable treatment is available.
• The study will collect data on the effectiveness and side effects of at least 13 targeted anti-cancer drugs that target more than 15 unique genomic variants.
• The study will be conducted at multiple clinical sites, including the Michigan Cancer Research Consortium, the Cancer Research Consortium of West Michigan, and the Carolinas Healthcare System.
• Routine clinical care costs will be covered by the patient's insurance plan, and patients will receive the anti-cancer drugs at no charge.

Sources:

• American Society of Clinical Oncology (ASCO)
• AstraZeneca
• Bristol-Myers Squibb
• Eli Lilly and Company
• Genentech
• Pfizer
• Syapse
• Illumina
• Netherlands Center for Personalized Cancer Treatment